Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”

Validation of the American Association for the Study of Liver Disease/European Association for the Study of the Liver Multistep Screening Strategies for Metabolic Dysfunction-associated Steatotic Liver disease
by: Clémence Marie Canivet, et al.
Published: (2025-01-01)

Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease
by: Joana D’Arc Matos França de Abreu, et al.
Published: (2024-11-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening
by: Yong Jun Choi, et al.
Published: (2025-04-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01)

Hyperferritinemia and the Risk of Liver Fibrosis and Liver-Related Events in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Simona Cernea, et al.
Published: (2025-08-01)

Association between alcohol consumption and hepatic fibrosis in Chinese adult males with metabolic dysfunction-associated steatotic liver disease
by: Mao Li, et al.
Published: (2025-04-01)

Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Amani Elshaer, et al.
Published: (2024-07-01)

Serum biomarkers in the metabolic dysfunction-associated steatotic liver fibrosis diagnosis in children
by: Yu.M. Stepanov, et al.
Published: (2024-12-01)

Prediction of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease by Type IV Collagen 7S
by: Hiroshi Ishiba, et al.
Published: (2025-01-01)

Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Hai Xu, et al.
Published: (2025-04-01)

Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
by: Zhifeng Gao, et al.
Published: (2025-01-01)

Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
by: Weixiong Zhu, et al.
Published: (2025-07-01)

Predictors of Significant Fibrosis Among People Living with HIV with Metabolic Dysfunction- Associated Steatotic Liver Disease
by: Thaninee Prasoppokakorn, et al.
Published: (2024-12-01)

Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Thaninee Prasoppokakorn
Published: (2025-01-01)

An epidemiological study on the factors including genetic polymorphism influencing ALT >30 U/L and liver fibrosis progression in metabolic dysfunction‐associated steatotic liver disease among the general population
by: Satoshi Sato, et al.
Published: (2024-12-01)

Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study
by: Ziping Song, et al.
Published: (2025-04-01)

Metabolic dysfunction-associated steatotic liver disease
by: Chieh Chen, et al.
Published: (2024-12-01)

Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage
by: Chuheng Gou, et al.
Published: (2025-12-01)

Nonlinear associations of the hs-CRP/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017–2018
by: Bin Liang, et al.
Published: (2025-02-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01)

An overview of pathogenesis of metabolic dysfunction-associated steatotic liver disease
by: Shahid Habib, et al.
Published: (2024-11-01)

A new Korean nomenclature for steatotic liver disease
by: Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
Published: (2024-09-01)

Allyl nonanoate as a novel bile-derived biomarker in metabolic dysfunction-associated steatotic liver disease
by: Soo Hyeon Lee, et al.
Published: (2025-10-01)

Cardiometabolic and genetic factors in the progression of metabolic dysfunction-associated steatotic liver disease
by: Veronika P. Gomonova, et al.
Published: (2025-01-01)

The moderating effect of dietary fiber intake on the association between sleep pattern and liver fibrosis in metabolic dysfunction-associated steatotic liver disease: a study from NHANES
by: Guoqing Jia, et al.
Published: (2024-12-01)

Human liver perfluorooctane sulfonate associates with steatotic liver disease in a sex-dependent manner
by: Emily Flam, et al.
Published: (2025-10-01)

Evaluation of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease using ultrasound controlled attenuation parameter combined with clinical features
by: LIU Chunyu, et al.
Published: (2024-10-01)

Prediction of hepatic fibrosis using the aspartate transaminase-to-platelet ratio index in children and adolescents with metabolic dysfunction-associated steatotic liver disease
by: Hye Young Jin, et al.
Published: (2024-11-01)

Association of high-sensitivity C-reactive protein with hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
by: Yunfei Wu, et al.
Published: (2025-02-01)

Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review
by: Prajith Raj Ramesh, et al.
Published: (2024-12-01)

Beyond Nonalcoholic Fatty Liver Disease: The Expansive Realm of Metabolic Dysfunction-associated Steatotic Liver Disease
by: Samir Samadarshi, et al.
Published: (2025-01-01)

Screening of advanced fibrosis and metabolic dysfunction-associated steatotic liver disease using transient elastography in vulnerable population
by: Robert Nastasa, et al.
Published: (2025-09-01)

ASSOCIATION BETWEEN ANXIETY AND DEPRESSION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
by: Eloyse Cristina BOTACIN, et al.
Published: (2024-07-01)

Association of metabolic dysfunction-associated steatotic liver disease and steatosis-associated fibrosis estimator with subclinical coronary atherosclerosis: observation cohort study
by: Joonho Jeong, et al.
Published: (2025-07-01)

Sarcopenia and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
by: Ludovico Abenavoli, et al.
Published: (2024-09-01)

NPR is an independent risk factor for predicting all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease: evidence from NHANES 2007–2020
by: Dan Ye, et al.
Published: (2025-04-01)